Volume 24, Number 11—November 2018
Research
Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010–2017
Kimiko Ubukata
, Misako Takata, Miyuki Morozumi, Naoko Chiba, Takeaki Wajima, Shigeo Hanada, Michi Shouji, Megumi Sakuma, Satoshi Iwata, and the Invasive Pneumococcal Diseases Surveillance Study Group
, Misako Takata, Miyuki Morozumi, Naoko Chiba, Takeaki Wajima, Shigeo Hanada, Michi Shouji, Megumi Sakuma, Satoshi Iwata, and the Invasive Pneumococcal Diseases Surveillance Study Group
Table 3
Distribution of pneumococcal serotypes in adults before PCV7 and after introduction of PCV7 and PCV13 administration to children, Japan, April 2010–March 2017*
| Serotype | No. (%) |
p value† | ||
|---|---|---|---|---|
| Pre-PCV7 period, 2010, n = 275 | PCV7 period, 2011–2013, n = 695 | PCV13 period, 2014–2016, n = 880 | ||
| PCV7 | ||||
| 4 | 14 (5.1) | 27 (3.9) | 4 (0.5) | <0.001 |
| 6B | 42 (15.3) | 39 (5.6) | 22 (2.5) | <0.001 |
| 9V | 7 (2.5) | 7 (1.0) | 6 (0.7) | 0.042 |
| 14 | 21 (7.6) | 41 (5.9) | 6 (0.7) | <0.001 |
| 18C | 1 (0.4) | 3 (0.4) | 2 (0.2) | 0.642 |
| 19F | 14 (5.1) | 23 (3.3) | 15 (1.7) | 0.007 |
| 23F | 21 (7.6) | 28 (4.0) | 9 (1.0) | <0.001 |
| Subtotal |
120 (43.6) |
168 (24.2) |
64 (7.3) |
<0.001 |
| PCV13–nonPCV7‡ | ||||
| 1 | 1 (0.4) | 4 (0.6) | 13 (1.5) | 0.145 |
| 3 | 45 (16.4) | 110 (15.8) | 145 (16.5) | 0.939 |
| 5 | 0 | 1 (0.1) | 0 | NA |
| 6A | 11 (4.0) | 16 (2.3) | 9 (1.0) | 0.006 |
| 7F | 9 (3.3) | 9 (1.3) | 33 (3.8) | 0.006 |
| 19A | 18 (6.5) | 61 (8.8) | 99 (11.3) | 0.045 |
| Subtotal |
84 (30.5) |
201 (28.9) |
299 (34.0) |
0.093 |
| PPSV23–nonPCV13§ | ||||
| 8 | 0 | 2 (0.3) | 0 | NA |
| 10A | 10 (3.6) | 34 (4.9) | 54 (6.1) | 0.244 |
| 11A | 3 (1.1) | 23 (3.3) | 34 (3.9) | 0.058 |
| 12F | 5 (1.8) | 5 (0.7) | 63 (7.2) | <0.001 |
| 15B | 3 (1.1) | 14 (2.0) | 10 (1.1) | 0.356 |
| 20 | 1 (0.4) | 7 (1.0) | 14 (1.6) | 0.261 |
| 22F | 10 (3.6) | 63 (9.1) | 59 (6.7) | 0.008 |
| 33F | 2 (0.7) | 4 (0.6) | 11 (1.3) | 0.352 |
| Subtotal |
34 (12.4) |
152 (21.9) |
245 (27.8) |
<0.001 |
| NVT | ||||
| 6C | 13 (4.7) | 49 (7.1) | 52 (5.9) | 0.400 |
| 15A | 6 (2.2) | 28 (4.0) | 47 (5.3) | 0.068 |
| 15C | 0 | 12 (1.7) | 7 (0.8) | 0.034 |
| 23A | 2 (0.7) | 33 (4.7) | 50 (5.7) | <0.001 |
| 24F | 0 | 11 (1.6) | 16 (1.8) | 0.049 |
| 34 | 1 (0.4) | 5 (0.7) | 12 (1.4) | 0.301 |
| 35B | 7 (2.5) | 22 (3.2) | 55 (6.3) | 0.004 |
| 38 | 3 (1.1) | 7 (1.0) | 11 (1.3) | 0.955 |
| Other¶ | 5 (1.8) | 6 (0.9) | 22 (2.5) | 0.042 |
| Subtotal | 37 (13.5) | 173 (24.9)# | 272 (30.9) | <0.001 |
*Years run April 1– March 31 of the following year. NA, not applicable; NVT, nonvaccine serotype; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
†p values compare the 3 surveillance periods; boldface indicates significant increase.
‡Serotypes added to PCV7.
§Serotypes contained in PPSV23 but not PCV13.
¶Includes 6D (n = 2), 7C (n = 8), 13 (n = 1), 16F (n = 6), 18B (n = 1), 23B (n = 5), 31 (n = 3), and 37 (n = 7).
#One strain identified as nontypeable was excluded from the table.
Page created: October 17, 2018
Page updated: October 17, 2018
Page reviewed: October 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.